Business Segments · Acquired in-process research and development expenses
Pharmaceuticals — Acquired in-process research and development expenses
Vertex Pharmaceuticals Pharmaceuticals — Acquired in-process research and development expenses increased by 3.7% to $56.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 35.4%, from $87.50M to $56.50M. Over 3 years (FY 2022 to FY 2025), Pharmaceuticals — Acquired in-process research and development expenses shows an upward trend with a 4.8% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2022
Last reportedQ4 2025
Rolls up toAcquired IPR&D Expense
How to read this metric
High values indicate aggressive external growth and pipeline expansion through M&A or licensing.
Detailed definition
One-time costs related to the acquisition of research and development projects from other companies or through licensing...
Peer comparison
Common in biotech; peers often report this as 'In-Process R&D' (IPR&D) charges.
Metric ID:
vrtx_segment_pharmaceuticals_acquired_in_process_research_and_development_expensesHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $28.88M | $28.88M | $28.88M | $28.88M | $131.78M | $131.78M | $131.78M | $131.78M | $76.80M | $4.45B | $15.00M | $87.50M | $19.80M | $2.20M | $54.50M | $56.50M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +356.4% | +0.0% | +0.0% | +0.0% | -41.7% | >999% | -99.7% | +483.3% | -77.4% | -88.9% | >999% | +3.7% |
| YoY Change | — | — | — | — | +356.4% | +356.4% | +356.4% | +356.4% | -41.7% | >999% | -88.6% | -33.6% | -74.2% | -100.0% | +263.3% | -35.4% |
Range$2.20M – $4.45B
CAGR+19.6%
Avg YoY Growth+382.6%
Median YoY Growth+114.9%
Current Streak2 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's pharmaceuticals — acquired in-process research and development expenses?
- Vertex Pharmaceuticals (VRTX) reported pharmaceuticals — acquired in-process research and development expenses of $56.50M in Q4 2025.
- How has Vertex Pharmaceuticals's pharmaceuticals — acquired in-process research and development expenses changed year-over-year?
- Vertex Pharmaceuticals's pharmaceuticals — acquired in-process research and development expenses decreased by 35.4% year-over-year, from $87.50M to $56.50M.
- What is the long-term trend for Vertex Pharmaceuticals's pharmaceuticals — acquired in-process research and development expenses?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's pharmaceuticals — acquired in-process research and development expenses has grown at a 4.8% compound annual growth rate (CAGR), from $115.50M to $133.00M.
- What does pharmaceuticals — acquired in-process research and development expenses mean?
- Costs paid to acquire external research projects or drug candidates from other companies.